OASIS 2 trial: what the oral Wegovy clinical data actually shows

# OASIS 2 trial: what the oral Wegovy clinical data actually shows

When a new medicine makes headlines, the numbers get simplified. “15% weight loss” becomes a slogan rather than a data point. For anyone actually considering oral Wegovy — or already taking it — the more useful question is: what did the trial really show, who was in it, and what does it mean in the real world?

This guide is a plain-English walkthrough of the OASIS 2 trial. No hype, no glossing over the limitations. Just what the data shows and what it honestly means for someone deciding whether oral semaglutide is right for them.

> Oral Wegovy is a prescription-only medicine. The trial data summarised here applies to the studied population under controlled conditions. Your own results will vary, and your prescriber is the right person to discuss what the evidence means for your individual situation.

—

## What OASIS 2 was

OASIS 2 (Oral semaglutide Anti-obesity Study Implementation of cardiovascular event reduction, Study 2) was a randomised, double-blind, placebo-controlled phase 3 clinical trial. It ran for 68 weeks and enrolled 667 adult participants.

Participants were randomly assigned to receive either oral semaglutide 50mg (the tablet formulation subsequently approved in the UK as 25mg Wegovy — note the different naming conventions between trial and licensed product) or a matched placebo. Neither participants nor researchers knew who was receiving which treatment until the trial ended. That double-blind design matters because it rules out placebo effect as an explanation for the results.

To be eligible, participants had to have a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related health condition such as high blood pressure, type 2 diabetes, or sleep apnoea. People with a history of certain cardiovascular events were excluded.

All participants also received lifestyle counselling — regular sessions on diet and physical activity — throughout the trial. This is important context for interpreting the results.

—

## The primary endpoint: 15.1% body weight reduction

The headline figure from OASIS 2 is a mean body weight reduction of 15.1% in the semaglutide group, compared with 2.5% in the placebo group, at 68 weeks. Both groups received the same lifestyle intervention — so the additional weight loss attributable to oral semaglutide was approximately 12.6 percentage points above placebo.

To put that in concrete terms: for someone starting at 100kg, a 15.1% reduction represents losing around 15kg over 68 weeks — roughly 17 months. The placebo group, receiving lifestyle support alone, lost around 2.5kg from the same starting weight.

The difference was statistically significant, meaning it is extremely unlikely to be due to chance.

—

## Responder analysis: how many people lost how much

Averages can be misleading. The responder data from OASIS 2 gives a better picture of what range of outcomes people actually experienced:

– **85% of participants** in the semaglutide group lost at least 5% of body weight
– **68% of participants** lost at least 10% of body weight
– **50% of participants** lost at least 15% of body weight
– **34% of participants** lost at least 20% of body weight

In the placebo group, the equivalent figures were approximately 26%, 13%, 6%, and 3%.

This distribution is important because it shows that while the average result was 15.1%, roughly half of participants achieved more than that and half achieved less. A meaningful proportion — around one in three — achieved 20% or greater weight reduction. At the same time, around 15% of people in the semaglutide group did not reach the 5% threshold that many clinicians consider a minimum meaningful response.

—

## How OASIS 2 compares to OASIS 1

OASIS 1 tested the same oral semaglutide formulation but in a different population — specifically participants without type 2 diabetes and with a slightly different demographic profile. OASIS 1 reported a mean weight reduction of approximately 17.4% at 68 weeks. The difference between the two trials reflects variation in the study populations rather than any difference in the medicine itself.

It is also worth noting that the injectable form of semaglutide (Wegovy 2.4mg weekly, tested in the STEP 1 trial) showed an average weight reduction of approximately 14.9% at 68 weeks. This places oral and injectable semaglutide in a similar territory of effectiveness when studied under trial conditions — a finding that surprised many clinicians, given that oral bioavailability of semaglutide is lower than injectable.

The comparison is not perfectly direct — different trials, different populations, different conditions — but it does suggest oral semaglutide is a genuinely effective option rather than a weaker compromise.

—

## The limitations: what the trial cannot tell you

Being honest about what OASIS 2 does not show is as important as celebrating what it does.

**Trial populations are not the general population.** People who complete clinical trials tend to be more adherent, more motivated, and more closely monitored than average. They also receive regular lifestyle counselling that many people in the real world will not access with the same intensity or consistency. Trial results represent a best-case scenario in many respects.

**Completion rates matter.** Not everyone who started OASIS 2 completed it. Dropout — due to side effects, personal circumstances, or lack of response — is part of the picture. Responder analyses based only on completers can look more positive than the full intent-to-treat picture.

**68 weeks is not indefinite.** The trial tells us what happens over 68 weeks. It does not tell us what happens at year three, year five, or decade-long timescales. Long-term data on oral semaglutide continues to accumulate, but is not yet as extensive as the data on injectable semaglutide, which has been available longer.

**Individual variation is real.** The average is 15.1%. Some people will achieve 25%. Some will achieve 5%. Factors including genetics, baseline metabolic health, adherence to dosing instructions, and lifestyle factors all influence outcomes in ways that cannot be predicted in advance for any individual.

—

## What happens when treatment stops

This is the part of the semaglutide story that gets less attention in headlines, but is arguably the most important thing to understand before starting.

When participants in semaglutide trials stop treatment, weight regain is the norm. Studies of injectable semaglutide (including the STEP 1 extension study) show that within one to two years of stopping, participants regain the majority of the weight lost during treatment. There is no reason to expect oral semaglutide to behave differently.

This is not a failure of the medicine. It reflects the biology of weight regulation. Semaglutide does not fix the underlying mechanisms that make maintaining weight loss difficult for many people — it manages them while you are taking it, in the same way that antihypertensive medication manages blood pressure without curing hypertension.

What this means practically: oral Wegovy is most useful as a long-term treatment, not a short course. Decisions about how long to continue, whether to ever stop, and what to do if treatment is paused should be made in partnership with your prescriber.

—

## What the data means for someone deciding whether to try it

If you are weighing up whether to start oral Wegovy, here is what the OASIS 2 data honestly supports:

Oral semaglutide at 25mg, combined with lifestyle support, produces meaningful weight loss in a large proportion of people over 68 weeks. The majority of trial participants lost at least 10% of body weight. Around half lost 15% or more. These are clinically significant results — reductions of this magnitude are associated with improvements in blood pressure, cholesterol, blood sugar, joint load, and quality of life.

The medicine is not a short-term fix. It requires daily adherence to strict dosing conditions (30 minutes before food, plain water only), and the benefits appear to require continued treatment to be maintained.

It also requires a prescription from a registered UK healthcare provider. Oral Wegovy cannot be purchased over the counter. CompareWegovyPrices.co.uk helps you compare verified provider prices and find a registered UK provider — but the decision to start treatment is one for you and your clinician, not a website.

—

## The honest version: very effective, requires commitment

The OASIS 2 data is genuinely impressive. Average weight loss of 15.1%, with half of participants achieving 15% or more, puts oral semaglutide among the most effective non-surgical weight management treatments ever studied.

But the trial also shows — as does all the semaglutide evidence — that this is a treatment you take ongoing, not something you do for a year and then stop. The biology of weight regain is real and well-documented. Anyone starting oral Wegovy on the assumption that they will lose weight and then be fine without it is likely to be disappointed.

The people who do best with GLP-1 medicines tend to be those who understand this from the start — who see semaglutide as a long-term tool rather than a temporary fix, and who use the appetite changes it creates to build sustainable eating habits rather than simply restricting calories while the medicine is working.

If that sounds like the kind of commitment you are ready to make, the data suggests oral Wegovy is worth a serious conversation with your prescriber.

—

## Frequently asked questions

### What was the main finding of the OASIS 2 trial?

Participants taking oral semaglutide 25mg (plus lifestyle counselling) achieved an average body weight reduction of 15.1% over 68 weeks, compared with 2.5% in the placebo group. The trial involved 667 adults and was randomised and double-blind.

### How does OASIS 2 compare to the results with injectable Wegovy?

The STEP 1 trial of injectable semaglutide (2.4mg weekly) showed an average weight reduction of approximately 14.9% at 68 weeks. This places oral and injectable semaglutide in a similar effectiveness range, though the trials involved different populations and cannot be directly compared.

### Did everyone in the trial lose weight?

No. Around 85% of participants in the semaglutide group lost at least 5% of body weight, but approximately 15% did not reach this threshold. Individual results varied considerably, from modest losses to reductions above 20%.

### What happened to participants after the trial ended?

OASIS 2 ran for 68 weeks. Evidence from related semaglutide trials (including injectable semaglutide) consistently shows that weight regain occurs after stopping treatment. This is expected and reflects the biology of weight regulation rather than a failure of the treatment.

### Was the lifestyle support in the trial realistic?

Participants received regular structured lifestyle counselling throughout the trial. This is more intensive than many people will access in the real world, which may mean real-world results are somewhat lower than trial figures on average.

### Do I need a prescription to access oral Wegovy in the UK?

Yes. Oral Wegovy is a prescription-only medicine in the UK. It must be prescribed by a registered healthcare professional following an appropriate assessment. CompareWegovyPrices.co.uk helps you compare prices and find a registered UK provider, but cannot issue prescriptions.

—

*This article is for informational purposes only and does not constitute medical advice. Oral Wegovy (semaglutide) is a prescription-only medicine available in the UK. Always consult a registered UK healthcare professional before starting any weight management treatment. CompareWegovyPrices.co.uk is not affiliated with Novo Nordisk.*

What comes after the Wegovy tablet? The pipeline drugs to watch

The OASIS 2 trial established oral semaglutide as an effective, evidence-based treatment. But the pipeline behind it is advancing quickly. Drugs showing higher weight loss in current trials include:

• Retatrutide (triple GLP-1/GIP/glucagon agonist) — up to 24% weight loss in phase 2
• Orforglipron (oral small-molecule GLP-1, no fasting required) — ~15% in phase 3
• Full pipeline tracker — all drugs, all timelines

None are currently available in the UK, but understanding how oral semaglutide compares positions you to make informed decisions when they do arrive.